Cargando…
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468673/ https://www.ncbi.nlm.nih.gov/pubmed/30857358 http://dx.doi.org/10.3390/cancers11030341 |
_version_ | 1783411488088653824 |
---|---|
author | Rachiglio, Anna Maria Fenizia, Francesca Piccirillo, Maria Carmela Galetta, Domenico Crinò, Lucio Vincenzi, Bruno Barletta, Emiddio Pinto, Carmine Ferraù, Francesco Lambiase, Matilde Montanino, Agnese Roma, Cristin Ludovini, Vienna Montagna, Elisabetta Sara De Luca, Antonella Rocco, Gaetano Botti, Gerardo Perrone, Francesco Morabito, Alessandro Normanno, Nicola |
author_facet | Rachiglio, Anna Maria Fenizia, Francesca Piccirillo, Maria Carmela Galetta, Domenico Crinò, Lucio Vincenzi, Bruno Barletta, Emiddio Pinto, Carmine Ferraù, Francesco Lambiase, Matilde Montanino, Agnese Roma, Cristin Ludovini, Vienna Montagna, Elisabetta Sara De Luca, Antonella Rocco, Gaetano Botti, Gerardo Perrone, Francesco Morabito, Alessandro Normanno, Nicola |
author_sort | Rachiglio, Anna Maria |
collection | PubMed |
description | Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations (other mutations) on the outcome of 133 EGFR mutant patients, who received first-line therapy with EGFR TKIs between June 2008 and December 2014. Analysis of genomic DNA by Next Generation Sequencing (NGS) revealed the presence of hotspot mutations in genes other than the EGFR, including KRAS, NRAS, BRAF, ERBB2, PIK3CA, or MET, in 29/133 cases (21.8%). A p.T790M mutation was found in 9/133 tumour samples (6.8%). The progression free survival (PFS) of patients without other mutations was 11.3 months vs. 7 months in patients with other mutations (log-rank test univariate: p = 0.047). In a multivariate Cox regression model including the presence of other mutations, age, performance status, smoking status, and the presence of p.T790M mutations, the presence of other mutations was the only factor significantly associated with PFS (Hazard Ratio 1.63, 95% CI 1.04–2.58; p = 0.035). In contrast, no correlation was found between TP53 mutations and patients’ outcome. These data suggest that a subgroup of EGFR mutant tumours have concomitant driver mutations that might affect the activity of first-line EGFR TKIs. |
format | Online Article Text |
id | pubmed-6468673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64686732019-04-24 The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients Rachiglio, Anna Maria Fenizia, Francesca Piccirillo, Maria Carmela Galetta, Domenico Crinò, Lucio Vincenzi, Bruno Barletta, Emiddio Pinto, Carmine Ferraù, Francesco Lambiase, Matilde Montanino, Agnese Roma, Cristin Ludovini, Vienna Montagna, Elisabetta Sara De Luca, Antonella Rocco, Gaetano Botti, Gerardo Perrone, Francesco Morabito, Alessandro Normanno, Nicola Cancers (Basel) Article Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations (other mutations) on the outcome of 133 EGFR mutant patients, who received first-line therapy with EGFR TKIs between June 2008 and December 2014. Analysis of genomic DNA by Next Generation Sequencing (NGS) revealed the presence of hotspot mutations in genes other than the EGFR, including KRAS, NRAS, BRAF, ERBB2, PIK3CA, or MET, in 29/133 cases (21.8%). A p.T790M mutation was found in 9/133 tumour samples (6.8%). The progression free survival (PFS) of patients without other mutations was 11.3 months vs. 7 months in patients with other mutations (log-rank test univariate: p = 0.047). In a multivariate Cox regression model including the presence of other mutations, age, performance status, smoking status, and the presence of p.T790M mutations, the presence of other mutations was the only factor significantly associated with PFS (Hazard Ratio 1.63, 95% CI 1.04–2.58; p = 0.035). In contrast, no correlation was found between TP53 mutations and patients’ outcome. These data suggest that a subgroup of EGFR mutant tumours have concomitant driver mutations that might affect the activity of first-line EGFR TKIs. MDPI 2019-03-10 /pmc/articles/PMC6468673/ /pubmed/30857358 http://dx.doi.org/10.3390/cancers11030341 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rachiglio, Anna Maria Fenizia, Francesca Piccirillo, Maria Carmela Galetta, Domenico Crinò, Lucio Vincenzi, Bruno Barletta, Emiddio Pinto, Carmine Ferraù, Francesco Lambiase, Matilde Montanino, Agnese Roma, Cristin Ludovini, Vienna Montagna, Elisabetta Sara De Luca, Antonella Rocco, Gaetano Botti, Gerardo Perrone, Francesco Morabito, Alessandro Normanno, Nicola The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients |
title | The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients |
title_full | The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients |
title_fullStr | The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients |
title_full_unstemmed | The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients |
title_short | The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients |
title_sort | presence of concomitant mutations affects the activity of egfr tyrosine kinase inhibitors in egfr-mutant non-small cell lung cancer (nsclc) patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468673/ https://www.ncbi.nlm.nih.gov/pubmed/30857358 http://dx.doi.org/10.3390/cancers11030341 |
work_keys_str_mv | AT rachiglioannamaria thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT feniziafrancesca thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT piccirillomariacarmela thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT galettadomenico thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT crinolucio thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT vincenzibruno thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT barlettaemiddio thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT pintocarmine thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT ferraufrancesco thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT lambiasematilde thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT montaninoagnese thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT romacristin thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT ludovinivienna thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT montagnaelisabettasara thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT delucaantonella thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT roccogaetano thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT bottigerardo thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT perronefrancesco thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT morabitoalessandro thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT normannonicola thepresenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT rachiglioannamaria presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT feniziafrancesca presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT piccirillomariacarmela presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT galettadomenico presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT crinolucio presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT vincenzibruno presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT barlettaemiddio presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT pintocarmine presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT ferraufrancesco presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT lambiasematilde presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT montaninoagnese presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT romacristin presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT ludovinivienna presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT montagnaelisabettasara presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT delucaantonella presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT roccogaetano presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT bottigerardo presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT perronefrancesco presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT morabitoalessandro presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients AT normannonicola presenceofconcomitantmutationsaffectstheactivityofegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancernsclcpatients |